NASDAQ: LMAT
- Last Close 57.00
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Investment Style Small Growth
- Day Range 55.07 – 56.75
- Year Range 41.78 – 68.67
- Market Cap 1.2418 Bil
- Volume / Avg 112,974.0 / 101,882.8
- Price / Sales 7.17
- Price / Book 4.47
- Forward Div Yield 0.84%
- Trailing Div Yield 0.98%
Morningstar‘s Stock Analysis LMAT
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile LMAT
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of LMAT’s competitive advantage.
LeMaitre Vascular Inc
XNAS: LMAT
| Boston Scientific Corp
XNYS: BSX
| Edwards Lifesciences Corp
XNYS: EW
| Medtronic PLC
XNYS: MDT
| |
Price
| 55.78 | 53.80 | 69.46 | 79.97 |
Currency
| USD | USD | USD | USD |
Change
| −$1.22 (2.14%) | +$0.20 (0.37%) | −$0.20 (0.29%) | −$0.30 (0.37%) |
Market Cap
| 1.24 Bil | 78.78 Bil | 42.23 Bil | 106.40 Bil |
Industry
| Medical Instruments & Supplies | Medical Devices | Medical Devices | Medical Devices |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for LeMaitre Vascular Inc Stock
Yes. LMAT has a forward dividend yield of 0.98%.
See
LMAT’s full dividends and stock split history
on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
LMAT’s market cap is 1.24 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
LMAT’s stock style is Small Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
LMAT’s price/sales is 7.17.
Price/sales represents the amount an investor is willing to pay for a dollar generated from
a particular company’s sales or revenues.
LMAT’s price/forward earnings is 50.44.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates.
The lower the Forward P/E, the cheaper the stock.
LMAT’s price/book is 4.47.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets,
based on historical, rather than current, valuations. Historical valuations generally do not reflect
a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See LMAT’s valuation ratios compared to the Market Index.
LMAT’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare LMAT’s historical performance against its industry peers and the overall market.